+

WO2006021814A3 - Medicament - Google Patents

Medicament Download PDF

Info

Publication number
WO2006021814A3
WO2006021814A3 PCT/GB2005/050108 GB2005050108W WO2006021814A3 WO 2006021814 A3 WO2006021814 A3 WO 2006021814A3 GB 2005050108 W GB2005050108 W GB 2005050108W WO 2006021814 A3 WO2006021814 A3 WO 2006021814A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
well
product
products
methods
Prior art date
Application number
PCT/GB2005/050108
Other languages
English (en)
Other versions
WO2006021814A2 (fr
Inventor
Deirdre Mcintosh
Original Assignee
Aimsco Ltd
Deirdre Mcintosh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0415359.9A external-priority patent/GB0415359D0/en
Priority to EP05758978A priority Critical patent/EP1765377A2/fr
Application filed by Aimsco Ltd, Deirdre Mcintosh filed Critical Aimsco Ltd
Priority to MX2007000144A priority patent/MX2007000144A/es
Priority to JP2007519893A priority patent/JP2008505878A/ja
Priority to NZ552412A priority patent/NZ552412A/en
Priority to US11/631,067 priority patent/US20080207500A1/en
Priority to AU2005276242A priority patent/AU2005276242B2/en
Priority to EA200700115A priority patent/EA011389B1/ru
Priority to KR1020077002992A priority patent/KR101235723B1/ko
Priority to BRPI0513062-0A priority patent/BRPI0513062A/pt
Priority to CA002572777A priority patent/CA2572777A1/fr
Publication of WO2006021814A2 publication Critical patent/WO2006021814A2/fr
Priority to IL180487A priority patent/IL180487A/en
Publication of WO2006021814A3 publication Critical patent/WO2006021814A3/fr
Priority to US13/544,413 priority patent/US20130203669A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)

Abstract

L'analyse d'un produit du sérum de chèvre possédant de nombreux effets thérapeutique est décrite. Ce produit est identifié comme contenant de la pro-opiomélanocortine (POMC) ainsi que des peptides de corticolibérine , ainsi que des produits de dégradation de ces peptides. Des méthodes de traitement de maladies, dont le cancer, la sclérose en plaques et des troubles neurologiques, à l'aide de ces peptides et de leurs produits, que des médicaments comprenant lesdits peptides ainsi que des méthodes de production de ces peptides sont décrits.
PCT/GB2005/050108 2004-07-08 2005-07-08 Medicament WO2006021814A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EA200700115A EA011389B1 (ru) 2004-07-08 2005-07-08 Лекарственное средство
AU2005276242A AU2005276242B2 (en) 2004-07-08 2005-07-08 Medicament
MX2007000144A MX2007000144A (es) 2004-07-08 2005-07-08 Medicamento.
JP2007519893A JP2008505878A (ja) 2004-07-08 2005-07-08 医薬
NZ552412A NZ552412A (en) 2004-07-08 2005-07-08 Use of corticotropin releasing factor in the treatment of neural disorders
US11/631,067 US20080207500A1 (en) 2004-07-08 2005-07-08 Medicament
KR1020077002992A KR101235723B1 (ko) 2004-07-08 2005-07-08 약제
EP05758978A EP1765377A2 (fr) 2004-07-08 2005-07-08 Medicament
CA002572777A CA2572777A1 (fr) 2004-07-08 2005-07-08 Medicament comportant un facteur de liberation de corticotrophine et de la pro-opiomelanocortine et son utilisation
BRPI0513062-0A BRPI0513062A (pt) 2004-07-08 2005-07-08 composição farmacêutica, método de estimular a produção de pomc em um paciente, usos de um peptìdeo de crf isolado e de um peptìdeo de pomc isolado, e, métodos de tratamento para uma doença, de produzir crf e de tratamento curativo, melhorador ou profilático de uma doença
IL180487A IL180487A (en) 2004-07-08 2007-01-01 Corticotropin releasing factor (crf) for treatment of neural disorders
US13/544,413 US20130203669A1 (en) 2004-07-08 2012-07-09 Medicament

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0415359.9 2004-07-08
GBGB0415359.9A GB0415359D0 (en) 2004-07-08 2004-07-08 Medicament
GB0423386.2 2004-10-21
GBGB0423386.2A GB0423386D0 (en) 2004-07-08 2004-10-21 Medicament

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US63103708A Continuation 2004-07-08 2008-01-28

Publications (2)

Publication Number Publication Date
WO2006021814A2 WO2006021814A2 (fr) 2006-03-02
WO2006021814A3 true WO2006021814A3 (fr) 2007-03-29

Family

ID=35967903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/050108 WO2006021814A2 (fr) 2004-07-08 2005-07-08 Medicament

Country Status (7)

Country Link
EP (1) EP1765377A2 (fr)
JP (1) JP2008505878A (fr)
KR (1) KR101235723B1 (fr)
AU (1) AU2005276242B2 (fr)
BR (1) BRPI0513062A (fr)
CA (1) CA2572777A1 (fr)
WO (1) WO2006021814A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0415359D0 (en) * 2004-07-08 2004-08-11 Aimsco Ltd Medicament
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
GB0600202D0 (en) * 2006-01-06 2006-02-15 Aimsco Ltd Treatment of HIV
US7807143B2 (en) 2006-10-18 2010-10-05 Research Development Foundation Alpha-MSH therapies for treatment of autoimmune disease
EP2197465A2 (fr) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Utilisation de l'angiotensine ii comme agent therapeutique, p.e. pour le traitement des infections de s. pneumoniae
WO2009043520A1 (fr) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043468A2 (fr) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
AU2009241813A1 (en) * 2008-04-30 2009-11-05 Neutron Row Methods of using corticotropin-releasing factor for the treatment of cancer
US20100203048A1 (en) 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer
GB0910032D0 (en) * 2009-06-11 2009-07-22 Aimsco Ltd Use of serum composition to reduce the levels of TNF and/or VEGF in mammals
US20130259875A1 (en) * 2010-05-11 2013-10-03 Questcor Pharmaceuticals, Inc. Acth for treatment of amyotrophic lateral sclerosis
EP2701728B1 (fr) * 2012-06-25 2015-05-06 Aimsco Limited Formulation comprenant crh et l'alpha-2-macroglobuline
WO2015033175A1 (fr) * 2013-09-06 2015-03-12 Zlatko Ademovic Combinaison de peptides endogènes de type pro-opiomélanocortine utilisables dans le cadre du traitement de maladies auto-immunes
GB201322948D0 (en) * 2013-12-23 2014-02-12 Aimsco Ltd Improved formulation
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
EP3978610A3 (fr) 2014-03-19 2022-08-24 Ionis Pharmaceuticals, Inc. Compositions permettant de moduler l'expression de l'ataxine 2
WO2017117496A1 (fr) 2015-12-31 2017-07-06 Ionis Pharmaceuticals, Inc. Méthodes pour diminuer l'expression de l'ataxine-2
GB201617175D0 (en) 2016-10-10 2016-11-23 Iconic Intellectual Property Limited Assay
SG11202100077PA (en) 2018-07-25 2021-02-25 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn2 expression
GB201911063D0 (en) 2019-08-02 2019-09-18 Tarian Biologics Ltd Formulations
GB201911064D0 (en) 2019-08-02 2019-09-18 Tarian Biologics Ltd Therapy
KR102551880B1 (ko) * 2020-11-13 2023-07-05 성균관대학교산학협력단 부신피질자극호르몬분비호르몬을 유효성분으로 포함하는 신경세포구 형성 촉진용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5306710A (en) * 1989-07-28 1994-04-26 Regents Of The University Of California Method for treating endotoxin shock with CRF
WO1995023214A1 (fr) * 1994-02-28 1995-08-31 Ludwig Institute For Cancer Research Stimulation de la proliferation de cellules coliques en utilisant pomc¿76-103?
WO2002067996A2 (fr) * 2001-02-24 2002-09-06 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Agent servant a combattre la douleur localement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4407489A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
US20030186867A1 (en) * 2000-03-31 2003-10-02 Laura Facci Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases
AU2003202093B2 (en) * 2001-07-02 2010-05-13 Aimsco Limited Treatment of MS with goat serum
NZ530393A (en) * 2001-07-02 2006-10-27 Aimsco Ltd High titre antibodies to FAS (CD95/Apo-1) might lead to the inhibition of toxic chemokines, which are thought to be involved in MS induced disability

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5306710A (en) * 1989-07-28 1994-04-26 Regents Of The University Of California Method for treating endotoxin shock with CRF
WO1995023214A1 (fr) * 1994-02-28 1995-08-31 Ludwig Institute For Cancer Research Stimulation de la proliferation de cellules coliques en utilisant pomc¿76-103?
WO2002067996A2 (fr) * 2001-02-24 2002-09-06 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Agent servant a combattre la douleur localement

Also Published As

Publication number Publication date
EP1765377A2 (fr) 2007-03-28
BRPI0513062A (pt) 2008-04-22
AU2005276242B2 (en) 2011-08-25
AU2005276242A1 (en) 2006-03-02
KR101235723B1 (ko) 2013-02-21
WO2006021814A2 (fr) 2006-03-02
JP2008505878A (ja) 2008-02-28
KR20070042546A (ko) 2007-04-23
CA2572777A1 (fr) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2006021814A3 (fr) Medicament
WO2004065423A3 (fr) Molecules de reconnaissance pour le traitement et la detection de tumeurs
WO2005102287A3 (fr) Compositions pharmaceutiques pour therapie aux glucocorticoides aigue
WO2005059106A3 (fr) Anticorps contre l'interferon alpha et leur utilisations
WO2005078124A3 (fr) Marqueur diagnostique pour le cancer
IL172613A (en) Antibodies that bind at least two different human inhibitory kir gene products, hybridomas producing said antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies and use thereof for the manufacture of a medicament to potentiate nk cell activity
WO2005014525A3 (fr) Compose bi-aryle presentant une activite immunosuppressive
WO2004071382A3 (fr) Heterocycles substitues
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2012116229A3 (fr) Compositions et procédés pour le traitement de profilage de tumeur personnalisé
Lee et al. Effects of magnolialide isolated from the leaves of Laurus nobilis L.(Lauraceae) on immunoglobulin E-mediated type I hypersensitivity in vitro
WO2006048449A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
WO2002087596A3 (fr) Nouvelle indication therapeutique d'azithromycine pour le traitement des maladies inflammatoires non infectieuses
GB0415359D0 (en) Medicament
AU2003281619A1 (en) aPC NON-NEUTRALIZING ANTIBODY
WO2006048450A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
WO2004030618A3 (fr) Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires
WO2006018632A3 (fr) Therapie cellulaire
WO2006048452A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
TW200510437A (en) Phosphinane compound with immunomodulating activity
WO2006110577A3 (fr) Methodes et compositions pour reduire la production de cytokines pro-inflammatoires
WO2007054269A3 (fr) Extraits d'ecorce de varietes de corynanthe, utilisation de ceux-ci et medicaments, aliments dietetiques et preparations pharmaceutiques contenant ces extraits
ATE271871T1 (de) Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden
WO2004033710A3 (fr) Haplotypes du gene itgb3 et effets de doses d'atorvastatine sur le cholesterol hdl
DE602005004026D1 (de) Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005276242

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 180487

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2572777

Country of ref document: CA

Ref document number: 552412

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007519893

Country of ref document: JP

Ref document number: 12007500061

Country of ref document: PH

Ref document number: 2007/00286

Country of ref document: ZA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005758978

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 598/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200700115

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005276242

Country of ref document: AU

Date of ref document: 20050708

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005276242

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077002992

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580028451.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005758978

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11631067

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0513062

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载